RBC Adjusts Price Target on PTC Therapeutics to $81 From $82, Maintains Sector Perform Rating
RBC has revised its price target for PTC Therapeutics (PTCT) to $81, down from $82, while keeping a "Sector Perform" rating on the stock. This adjustment comes after the company's recent Q4 2025 earnings report, which included a loss of $1.67 per share and revenue of $164.7M, missing FactSet estimates. The report also followed the withdrawal of an NDA resubmission for Translarna due to FDA feedback.
Duchenne Muscular Dystrophy Therapeutics Market to Reach USD 11.31 Billion by 2033 at 9.24% CAGR; North America Leads with 45% Share - Key Players: Sarepta Therapeutics, Inc., PTC Therapeutics, Inc., F. Hoffmann-La Roche Ltd
The global Duchenne Muscular Dystrophy (DMD) therapeutics market, valued at USD 5.31 billion in 2025, is projected to reach USD 11.31 billion by 2033, demonstrating a compound annual growth rate (CAGR) of 9.24% from 2026 to 2033. This growth is driven by increased awareness, advancements in genetic therapies, and a robust pipeline of new treatment options, with North America holding a leading 45% market share due to strong research funding and advanced healthcare infrastructure. Key players in this evolving market include Sarepta Therapeutics, Inc., PTC Therapeutics, Inc., and F. Hoffmann-La Roche Ltd.
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) EVP Sells 829 Shares of Stock
PTC Therapeutics (NASDAQ:PTCT) EVP Lee Scott Golden sold 829 shares of the company's stock on April 2nd for $67.99 per share, totaling $56,363.71. This sale, conducted under a Rule 10b5-1 plan to cover tax withholdings, decreased his holdings by 1.04% to 79,115 shares valued at approximately $5.38 million. This transaction is part of a series of insider sales by Golden this year, occurring alongside the company's recent earnings miss and a "Moderate Buy" average analyst rating with an $82.71 price target.
Golden Lee, PTC Therapeutics EVP, sells $56k in shares By Investing.com
Golden Lee Scott, Executive Vice President and Chief Medical Officer at PTC Therapeutics (NASDAQ:PTCT), sold 829 shares of common stock for approximately $56,363 to cover tax withholding obligations. This transaction occurred after the vesting of restricted stock units. Despite the stock's 57% gain over the past year, InvestingPro analysis suggests it might be slightly overvalued, even as analysts like Morgan Stanley, Cantor Fitzgerald, and Barclays have maintained or initiated Overweight ratings with positive price targets.
PTC Therapeutics (PTCT) CMO executes 829-share tax sell-to-cover
PTC Therapeutics' Chief Medical Officer, Lee Scott Golden, automatically sold 829 shares of common stock at $67.99 per share. This "sell-to-cover" transaction was to satisfy tax withholding obligations related to the vesting of 2,100 restricted stock units (RSUs) granted on April 24, 2023. Following this non-discretionary sale, Golden directly holds 79,115 shares of the company.
PTCT (NASDAQ: PTCT) Form 144: Insider proposes sale of 2,265 shares
A recent Form 144 filing indicates a proposed sale of 2,265 shares of PTC Therapeutics (NASDAQ: PTCT) common stock on April 6, 2026. This proposed sale is tied to an option granted on January 5, 2023. The filing also details several prior sales by insider Mark Boulding earlier in 2026, totaling over 20,000 shares across various dates, with Fidelity Brokerage Services LLC listed as the broker for the current proposed transaction.
PTCT Stock News Today | Earnings, Events & Price Alerts
This page provides a comprehensive overview of recent news and events related to PTCT stock, including appointments to the board, stock option approvals, and market analysis that could affect biotech stocks. It also details major market events like KKR's planned sale of CoolIT Systems, Dr. Vinay Prasad's departure from a regulatory agency impacting drug approvals, Plug Power's hydrogen offering, and Prudential's unauthorized data removal incident. Additionally, the article mentions activist investor Starboard Value's stake in Lamb Weston.
Almstead, PTC Therapeutics officer, sells $3.59 million in shares
Neil Gregory Almstead, Chief Technical Operations Officer at PTC Therapeutics (NASDAQ:PTCT), sold 51,953 shares of common stock for $3.59 million on April 1, 2026, through a pre-arranged trading plan. This sale follows a 45% surge in the company's stock over the past year, though InvestingPro suggests it might be overvalued. Almstead still directly owns 60,137 shares, and his spouse holds an additional 2,737 shares.
How Investors Are Reacting To PTC Therapeutics (PTCT) Adding Veteran Dealmaker Jessica Chutter To Its Board
PTC Therapeutics recently appointed Jessica Chutter, a veteran healthcare banker from Morgan Stanley, to its Board of Directors. This move adds significant capital-markets expertise, which could influence future financing and deal decisions for the company. The article discusses how this appointment, alongside Jefferies' cautious hold rating, might shape the investment outlook for PTC Therapeutics, especially given uncertainties around its rare disease portfolio and regulatory challenges like the Translarna NDA withdrawal.
PTCT (NASDAQ: PTCT) lists 829 vested shares for resale; insider sales detailed
PTC Therapeutics (NASDAQ: PTCT) has submitted a Form 144 notice, indicating an intent to resell 829 shares tied to restricted stock vesting on April 1, 2026. The filing also details open-market sales by Lee S. Golden over the previous three months, including various share amounts with corresponding proceeds. The securities are listed to be sold on NASDAQ.
Insiders sell shares at PTCT (NASDAQ: PTCT) under Rule 144, multiple trades
Insiders at PTC Therapeutics (PTCT), specifically Neil G. Almstead and Zheng Y. Almstead, have reported multiple sales of restricted stock under Rule 144. These sales, which occurred in early 2026, followed vesting events that spanned from 2016 to 2025. The transactions involve significant share counts and proceeds, with Fidelity Brokerage Services LLC listed as the broker.
Jefferies Downgrades PTC Therapeutics (PTCT) to 'Hold' with Price Target Adjustment | PTCT Stock News
Jefferies has downgraded PTC Therapeutics (PTCT) from a 'Buy' to a 'Hold' rating, lowering its price target from $91.00 to $76.00. This adjustment reflects a 16.48% decrease and follows a series of recent analyst actions with varying ratings and price targets. Despite the downgrade, the average one-year price target from 15 analysts is $86.07, suggesting a potential upside of 31.12% from the current price, though GuruFocus' GF Value estimates a 45.73% downside.
PTC Therapeutics (NASDAQ:PTCT) Earns "Hold" Rating from Jefferies Financial Group
Jefferies Financial Group reiterated a "Hold" rating on PTC Therapeutics (NASDAQ:PTCT) and lowered its price target to $76 from $91, indicating a potential upside of 14.9%. This follows PTC Therapeutics' significant Q4 earnings and revenue miss, alongside accelerated insider selling. Despite this, major institutions have increased their stakes in the company.
Jefferies Initiates PTC Therapeutics(PTCT.US) With Hold Rating, Announces Target Price $76
Jefferies has initiated coverage of PTC Therapeutics (PTCT.US) with a "Hold" rating. The firm has set a price target of $76 for the company's shares. This initiation signals Jefferies' current view on the stock's potential performance.
Is It Time To Reassess PTC Therapeutics (PTCT) After Mixed Multi Year Share Performance?
This article analyzes PTC Therapeutics (PTCT) through various valuation methods, including Discounted Cash Flow (DCF) and Price-to-Earnings (P/E) ratios, to determine if its current stock price reflects its intrinsic value. It suggests PTCT is undervalued based on these models and presents both bullish and bearish narratives that investors can consider for their outlook. The article highlights the company's recent stock performance and its position within the pharmaceuticals and biotech sector.
Vanguard disaggregates holdings; reports 0 PTC Therapeutics shares (PTCT)
Vanguard Group has filed an amendment to its Schedule 13G/A, reporting zero beneficial ownership of PTC Therapeutics (PTCT) common stock. This change is due to an internal realignment effective January 12, 2026, where certain subsidiaries now report their holdings separately in accordance with SEC Release No. 34-39538. Ashley Grim, Head of Global Fund Administration, signed the amendment on March 27, 2026.
A Look At PTC Therapeutics (PTCT) Valuation As Shares Reflect Mixed Recent Returns
PTC Therapeutics (PTCT), a rare-disease biopharma company, is currently trading at $67, showing a mixed performance with a 21.84% one-year return but a 14.71% decline over 90 days. Simply Wall St's narrative suggests the stock is undervalued with a fair value of $87.93, contingent on the successful launch of its drug Sephience and managing pressures in its Duchenne muscular dystrophy franchise. The article encourages investors to consider both the promises and risks and to broaden their research beyond this single stock.
PTC Therapeutics (PTCT) director receives new stock and option awards
Jessica Caroline Chutter, a director at PTC Therapeutics (PTCT), was granted new equity awards on March 24, 2026, including stock options for 3,475 and 2,896 shares at an exercise price of $64.54 per share. She also received 4,000 restricted stock units vesting over three years and 3,333 restricted stock units with vesting dates in June 2026 and January 2027. These transactions are compensation-related grants, not open-market purchases or sales.
New PTC Therapeutics (PTCT) director Jessica Chutter files initial Form 3
Jessica Caroline Chutter, a new director at PTC Therapeutics (PTCT), has filed an initial Form 3, which is a required statement of beneficial ownership for new insiders. This filing serves as a baseline disclosure of her insider status and does not report any stock transactions or holdings. The document indicates that no securities are beneficially owned and no derivative securities are listed.
PTC Therapeutics (NASDAQ:PTCT) Upgraded at Truist Financial
Truist Financial has upgraded PTC Therapeutics (NASDAQ:PTCT) to a "strong-buy" rating. This upgrade contributes to a consensus "Moderate Buy" rating for the company, with a target price of $82.79. The biopharmaceutical company recently missed quarterly earnings estimates, but the stock has seen significant insider selling and institutional investor activity.
PTC Therapeutics adds Jessica Chutter to board of directors
PTC Therapeutics, Inc. has appointed Jessica Chutter, former managing director and chair of biotechnology investment banking at Morgan Stanley, to its board of directors. Chutter brings over 40 years of experience in capital raising and strategic transactions, and previously advised PTC during her time at Morgan Stanley. This appointment comes as PTC Therapeutics, a biopharmaceutical company with a strong financial health score, continues its operational development and follows recent positive earnings reports and analyst ratings, despite a setback with its Translarna drug application.
PTC Therapeutics appoints Jessica Chutter to its board
PTC Therapeutics has announced the appointment of Jessica Chutter to its board of directors as a Class I director, effective March 24, 2026. Chutter brings over 40 years of experience in healthcare investment banking at Morgan Stanley, with previous roles including Managing Director, Vice Chair of Healthcare Investment Banking, and Chair of Biotechnology Investment Banking. This move aims to fill a vacancy on the Board.
Morgan Stanley biotech banker tied to $80B raises joins PTC board
PTC Therapeutics (NASDAQ: PTCT) has appointed Jessica Chutter, a former Managing Director and Chair of Biotechnology Investment Banking at Morgan Stanley, to its Board of Directors. Chutter, with over 40 years of experience, was involved in approximately $80 billion in capital raising and $85 billion in strategic transactions during her career. Her appointment is expected to help guide PTC's next stage of growth, leveraging her extensive expertise and previous advisory relationship with the company.
SG Americas Securities LLC Has $67.94 Million Stock Holdings in PTC Therapeutics, Inc. $PTCT
SG Americas Securities LLC significantly increased its stake in PTC Therapeutics, Inc. by 587.5% in Q4, now holding 894,461 shares valued at approximately $67.94 million. Despite the company missing quarterly earnings and revenue estimates, analysts maintain a "Moderate Buy" rating with an average target price of $82.79. Meanwhile, corporate insiders sold off shares worth about $9.95 million in the last quarter, reducing their ownership to 5.50%.
PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors
PTC Therapeutics (NASDAQ: PTCT) has appointed Jessica Chutter, a biotech banking pioneer with over 40 years of experience at Morgan Stanley, to its Board of Directors. Ms. Chutter is known for building and leading Morgan Stanley's biotechnology franchise and her expertise is expected to guide PTC Therapeutics in its next phase of growth. Her extensive background in capital raising and strategic transactions in the biotech sector will be valuable to the company.
JPMorgan Chase & Co. Trims Stock Position in PTC Therapeutics, Inc. $PTCT
JPMorgan Chase & Co. has reduced its stake in PTC Therapeutics, Inc. by 18.4%, selling 110,626 shares, though the biopharmaceutical company is seeing varied institutional investor activity. Insiders have sold shares totaling approximately $9.95 million, including significant sales by two executives in early March. Despite missing quarterly earnings and revenue estimates, analysts maintain a "Moderate Buy" consensus with an average target price of $82.79 for PTC Therapeutics.
Between PTC Therapeutics and Eli Lilly, Which Stock Looks Set to Break Out?
The article titled "Between PTC Therapeutics and Eli Lilly, Which Stock Looks Set to Break Out?" discusses a comparison between the two pharmaceutical companies. However, the provided content is largely navigational and footer text, rendering the article unreadable. No substantive data comparing PTC Therapeutics and Eli Lilly is available in the provided text.
PTC Therapeutics or Eli Lilly: Which Stock Has More Upside?
This article compares PTC Therapeutics (PTCT) and Eli Lilly (LLY) stocks, suggesting that PTCT offers greater upside due to superior revenue growth, better profitability, and a relatively lower valuation. It presents detailed financial metrics and historical market performance for both companies, highlighting PTCT's stronger growth rates and higher operating margins. The analysis also briefly touches upon portfolio investing as a more stable approach.
PTCT SEC Filings - Ptc Therapeutics 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors to access PTC Therapeutics (PTCT) SEC filings, including 10-K, 10-Q, and 8-K reports, as well as insider trading forms. It details the types of information found in these filings, such as financial results, regulatory approvals (like FDA approvals for Sephience), and significant corporate events. The platform also offers AI-powered summaries to help users quickly understand key points from these documents.
PTCT SEC Filings - Ptc Therapeutics 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors and traders seeking official regulatory documents for PTC Therapeutics (PTCT), including 10-K, 10-Q, 8-K forms, and insider trading reports. It highlights key filings, AI-powered summaries, and real-time updates from EDGAR, helping users understand financial results, regulatory developments, and corporate events. Recent filings include insider stock sales, FDA communication regarding vatiquinone, and restructuring of the Censa earn-out agreement.
What PTC Therapeutics (PTCT)'s FDA Leadership Shift Means For Its Gene and RNA Pipeline Narrative
The departure of an FDA official, previously considered a barrier to accelerated approvals in cell and gene therapies, has improved sentiment around PTC Therapeutics (PTCT). This shift could positively influence the perception of PTC's gene and RNA-based pipeline and its rare disease portfolio, though near-term focus remains on the Sephience launch and managing revenue concentration and cash burn. The company projects significant revenue and earnings growth by 2028, with a fair value indicating a 36% upside, yet some analysts hold more pessimistic views regarding future revenue and earnings.
PTC Therapeutics (PTCT) director exercises options, sells 15,167 shares
PTC Therapeutics director Stephanie Okey exercised stock options and sold 15,167 common shares in a pre-planned transaction on March 10, 2026. She acquired the shares at an exercise price of $33.63 per share and sold them at $70.00 per share under a Rule 10b5-1 trading plan. Following these transactions, Okey directly holds 8,000 shares of PTC Therapeutics common stock.
What PTC Therapeutics (PTCT)'s FDA Leadership Shift Means For Its Gene and RNA Pipeline Narrative
PTC Therapeutics (PTCT) saw an uplift in sentiment after an FDA official, previously considered a barrier to accelerated approvals in gene and RNA therapies, departed. This shift has investors reassessing regulatory risks for the sector, potentially improving the outlook for PTC's pipeline. The company's investment narrative now focuses on the global rollout of Sephience and its rare disease portfolio, though some analysts maintain a more cautious view on future revenue and earnings.
18 new PTC Therapeutics hires receive stock options, RSUs
PTC Therapeutics (NASDAQ: PTCT) has granted inducement equity awards to 18 new employees, comprising 14,550 non-statutory stock options and 17,515 restricted stock units (RSUs). These awards, approved on March 10, 2026, serve as hiring incentives under Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $68.56 and a 10-year term, with both options and RSUs vesting over four years, subject to continued employment.
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics, Inc. announced inducement grants consisting of non-statutory stock options and restricted stock units (RSUs) to 18 new employees. These awards, totaling 14,550 shares of common stock options and 17,515 RSUs, were approved on March 10, 2026, by PTC's Compensation Committee. The grants are part of the new hires' employment compensation, made under Nasdaq Inducement Grant Exception Rule 5635(c)(4), and vest over four years based on continued service.
FDA Shift Reframes PTC Therapeutics Regulatory Risks And Reward Profile
A recent FDA leadership change, perceived as easing regulatory hurdles for cell and gene therapies, has positively impacted PTC Therapeutics (PTCT). This shift reduces concerns about approval timelines and procedural roadblocks, making PTC's drug pipeline more appealing to investors despite existing risks such as negative shareholders' equity and anticipated declining earnings. The company's future performance will depend on whether this friendlier regulatory tone translates into smoother review processes and faster decisions for its late-stage programs.
Matthew Klein Sells 2,662 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock
Matthew Klein, CEO of PTC Therapeutics, sold 2,662 shares of the company's stock for approximately $170,580, reducing his holding by 0.67%. The sale comes as PTC Therapeutics significantly missed its quarterly earnings and revenue estimates, reporting a $1.67 loss per share against a $0.21 consensus. Despite the poor financial performance and the stock trading below its 50-day moving average, analysts have a "Moderate Buy" consensus rating with a price target of $82.79.
Stephanie Okey Sells 15,167 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock
PTC Therapeutics director Stephanie Okey sold 15,167 shares of the company's stock on March 10 at an average price of $70, totaling over $1 million, significantly reducing her stake. This transaction follows another sale of 6,333 shares on March 5. The stock saw a 3.5% decline after PTC Therapeutics reported a substantial quarterly earnings and revenue miss, though analysts maintain a "Moderate Buy" consensus rating with an average target price of $82.79.
B. Metzler seel. Sohn & Co. AG Invests $944,000 in PTC Therapeutics, Inc. $PTCT
B. Metzler seel. Sohn & Co. AG recently acquired a new stake of 15,382 shares, valued at approximately $944,000, in PTC Therapeutics during the third quarter. This investment comes despite the biopharmaceutical company reporting a significant earnings miss and a 22.7% year-over-year revenue decline, though analysts maintain a "Moderate Buy" rating with an $82.79 price target. Insider selling also occurred, with executives offloading shares worth $13.58 million last quarter.
FDA Shift Reframes PTC Therapeutics Regulatory Risks And Reward Profile
An FDA leadership change, perceived as easing regulatory hurdles for cell and gene therapies, has positively impacted biotech sentiment, directly affecting PTC Therapeutics (PTCT). This shift, stemming from the departure of an official cautious on accelerated approvals, highlights PTC's drug pipeline and could reframe investor focus from regulatory concerns to underlying data. While the company still faces risks like concentrated product offerings and negative shareholders' equity, a more supportive regulatory environment could make its risk-reward profile more appealing and aid pipeline progression.
PTC Therapeutics (+8.9%): FDA Leadership Change Spurs Sector-Wide Rally
PTC Therapeutics (PTCT) shares jumped 8.9% due to an FDA leadership change, perceived to ease regulatory risk for genetic medicine developers, rather than company-specific news. The departure of a key FDA director, Vinay Prasad, who was seen as a barrier to accelerated approvals, has led to a re-evaluation of approval odds across the rare disease and gene therapy sector. Despite the rally, the article emphasizes that the market has already priced in this news, highlighting the importance of predictive signals for future gains.
PTC Therapeutics (PTCT) CTO spouse sells shares under 10b5-1 trading plan
The spouse of Neil Gregory Almstead, Chief Technical Operations Officer at PTC Therapeutics (PTCT), sold 3,989 shares of common stock on March 5, 2026, at $63.38 per share. This transaction was conducted under a Rule 10b5-1 trading plan established on November 26, 2025. Following the sale, Almstead's spouse indirectly holds 2,737 shares, while Almstead directly holds 112,140 shares.
PTC Therapeutics (NASDAQ: PTCT) director sells 6,333 shares at $63.38
PTC Therapeutics director Stephanie Okey sold 6,333 shares of common stock at $63.38 per share on March 5, 2026, as part of a pre-arranged Rule 10b5-1 trading plan. Following this transaction, Okey directly holds 8,000 shares of PTC Therapeutics. The sale was documented in a Form 4 filing, indicating it was an open-market transaction.
Executive stock sale by PTC Therapeutics (PTCT) Chief Medical Officer
PTC Therapeutics' EVP & Chief Medical Officer, Lee Scott Golden, sold 10,000 shares of common stock at $63.38 per share on March 5, 2026. This transaction was conducted under a pre-established Rule 10b5-1 trading plan adopted on December 4, 2025. Following the sale, Golden directly owns 79,944 shares of PTC Therapeutics common stock.
PTC Therapeutics (+8.9%): FDA Leadership Change Spurs Sector-Wide Rally
PTC Therapeutics experienced an 8.9% stock surge, attributed not to company-specific news, but to a sector-wide rally in biotechnology, particularly for genetic medicine developers. This rally coincided with a perceived rerating of regulatory risk following the departure of a key FDA director, Vinay Prasad, whose strict stance on accelerated approvals was seen as a barrier. The article highlights that this significant market move has already been priced in, emphasizing the need for predictive signals over post-event notifications for investors.
PTC Therapeutics (+8.9%): FDA Leadership Change Spurs Sector-Wide Rally
PTC Therapeutics experienced an 8.9% increase, leading a sector-wide rally. This surge is attributed to a leadership change within the FDA. The article title suggests market optimism following the news.
(PTCT) Movement as an Input in Quant Signal Sets
This article from Stock Traders Daily discusses AI-generated quant signal sets for Ptc Therapeutics Inc. (NASDAQ: PTCT), highlighting a weak near and mid-term sentiment but a strong long-term outlook. It presents multiple trading strategies tailored to different risk profiles, including position, momentum, and risk hedging, along with multi-timeframe signal analysis. The analysis emphasizes an exceptional risk-reward setup targeting a 13.8% gain against a 0.3% risk.
Lee Scott Golden Sells 10,000 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock
Lee Scott Golden, Executive Vice President of PTC Therapeutics (NASDAQ:PTCT), sold 10,000 shares of the company's stock on March 5th for $633,800, reducing his ownership by over 11%. This sale follows recent poor quarterly earnings where PTC missed both EPS and revenue estimates. Despite this, the stock holds a "Moderate Buy" consensus rating from analysts with an average target price of $82.79.
Stephanie Okey Sells 6,333 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock
PTC Therapeutics Director Stephanie Okey sold 6,333 shares of the company's stock on March 5th for approximately $401,386, reducing her holdings by 44.18%. The sale came after PTC Therapeutics missed quarterly earnings and revenue expectations, reporting ($1.67) EPS against a projected ($0.21) and $164.68 million in revenue against $281.45 million expected. Despite the financial miss and insider selling, analysts maintain a "Moderate Buy" rating with a consensus price target of $82.79.
Jefferies Financial Group Acquires Stake in PTC Therapeutics
Jefferies Financial Group has acquired a significant stake in PTC Therapeutics, purchasing over 1.5 million shares valued at approximately $97.2 million. This investment makes Jefferies one of the largest shareholders, signaling Wall Street's confidence in PTC Therapeutics' pipeline of rare disease treatments. The acquisition highlights growing institutional interest in companies addressing unmet medical needs in specialty pharmaceuticals.
